RegenXBio (RGNX) Receives a Buy from Raymond James

Raymond James analyst Dane Leone maintained a Buy rating on RegenXBio (RGNX) on June 9. The company’s shares closed last Tuesday at $30.97.

According to, Leone is a 5-star analyst with an average return of 13.9% and a 63.3% success rate. Leone covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Allogene Therapeutics, and Ayala Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for RegenXBio with a $61.00 average price target, which is a 104.7% upside from current levels. In a report issued on August 4, Chardan Capital also reiterated a Buy rating on the stock with a $100.00 price target.

See today’s analyst top recommended stocks >>

Based on RegenXBio’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $17.64 million and GAAP net loss of $40.04 million. In comparison, last year the company earned revenue of $7.88 million and had a GAAP net loss of $1.46 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts